@article{oai:nagasaki-u.repo.nii.ac.jp:00001200,
 author = {Murata, Mika and Kosai, Kosuke and Yamauchi, Shunsuke and Sasaki, Daisuke and Kaku, Norihito and Uno, Naoki and Morinaga, Yoshitomo and Hasegawa, Hiroo and Miyazaki, Taiga and Izumikawa, Koichi and Mukae, Hiroshi and Yanagihara, Katsunori},
 issue = {4},
 journal = {Antimicrobial Agents and Chemotherapy},
 month = {Apr},
 note = {Lascufloxacin showed potent activity against Streptococcus pneumoniae with a GyrA or ParC mutation (first-step mutant). The frequency of selecting resistant strains tended to be lower for lascufloxacin than for levofloxacin and garenoxacin after drug exposure in first-step mutants but was similar in the comparison between lascufloxacin and moxifloxacin. The increase in MIC was smaller for lascufloxacin than for levofloxacin, garenoxacin, and moxifloxacin when clinical strains with only ParC mutations were exposed to the corresponding drug., Antimicrobial Agents and Chemotherapy, 62(4), 01971-17; 2018},
 title = {In Vitro Activity of Lascufloxacin against Streptococcus pneumoniae with Mutations in the Quinolone Resistance-Determining Regions},
 volume = {62},
 year = {2018}
}